Atlas Trials

Phase I Study of Comparing Single Dose JS005 (Recombinant Humanized Monoclonal Antibody Against IL-17A) With Placebo in Tolerability, Safety, Immunogenicity and Pharmacokinetic in Healthy Volunteers

Clinical trial NCT04220073 · COMPLETED

Trial details

NCT number
NCT04220073
Sponsor
Shanghai Junshi Bioscience Co., Ltd.
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Tolerability, Safety, Immunogenicity and Pharmacokinetic of JS005
Start date
2020-05-17
Primary completion
2020-11-20
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.